Consider the possibility that NWBO might have all PFS and OS data ready for hard data lock within two weeks, but might still be missing (for example) quality of life scores for a few patients. Calling a "soft lock" at that point would allow them to proceed on time with the key data analyses we all care about the most (and then publicly announce these results more quickly) rather than being held hostage to delays in obtaining non-critical data points. I think that makes perfect sense. People on the board bitching and moaning about not getting exact dates for things obviously have never run a large clinical trial (I have). It is complicated with a lot of unpredictable things, especially given the chaos now in healthcare institutions due to Covid-19 (for example, until very recently, most faculty and staff in my instition were prohibited from coming in to work and no elective surgeries or non-emergent in-person outpatient visits were allowed). Many companies avoid ambiguous data lock timing issues simply by not announcing when data lock occurs (e.g., Amarin), but NWBO in this case is communicating openly on this issue (a nice change of pace) and providing the most specific information they can at this point. The should get credit for trying, and topline results will be announced soon enough.
Market Data 
Markets 
AI
